Celgene submits EU marketing pitch for luspatercept; Bausch Health wins FDA approval for topical psoriasis treatment
→ Celgene and partner Acceleron have submitted an EU marketing application for their their red blood cell boosting drug luspatercept weeks after submitting an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
